472 related articles for article (PubMed ID: 32359489)
1. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
[TBL] [Abstract][Full Text] [Related]
2. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.
Vokinger KN; Hwang TJ; Carl DL; Laube Y; Ludwig WD; Naci H; Kesselheim AS
Lancet Oncol; 2022 Apr; 23(4):514-520. PubMed ID: 35271804
[TBL] [Abstract][Full Text] [Related]
3. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
[TBL] [Abstract][Full Text] [Related]
5. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
Del Paggio JC; Sullivan R; Schrag D; Hopman WM; Azariah B; Pramesh CS; Tannock IF; Booth CM
Lancet Oncol; 2017 Jul; 18(7):887-894. PubMed ID: 28583794
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
Adam R; Tibau A; Molto Valiente C; Šeruga B; Ocaña A; Amir E; Templeton AJ
PLoS One; 2022; 17(6):e0268545. PubMed ID: 35687539
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
Vivot A; Jacot J; Zeitoun JD; Ravaud P; Crequit P; Porcher R
Ann Oncol; 2017 May; 28(5):1111-1116. PubMed ID: 28453694
[TBL] [Abstract][Full Text] [Related]
8. The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017.
Rodwin MA; Mancini J; Duran S; Jalbert AC; Viens P; Maraninchi D; Gonçalves A; Marino P
Eur J Cancer; 2021 Mar; 145():11-18. PubMed ID: 33412466
[TBL] [Abstract][Full Text] [Related]
9. Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs.
Becker DJ; Lin D; Lee S; Levy BP; Makarov DV; Gold HT; Sherman S
J Oncol Pract; 2017 Jul; 13(7):e653-e665. PubMed ID: 28493760
[TBL] [Abstract][Full Text] [Related]
10. Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020.
Luo J; Ou S; Wei H; Qin X; Peng R; Wang S; Jiang Q
Front Public Health; 2023; 11():1109668. PubMed ID: 36908440
[TBL] [Abstract][Full Text] [Related]
11. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time.
Saluja R; Arciero VS; Cheng S; McDonald E; Wong WWL; Cheung MC; Chan KKW
J Oncol Pract; 2018 May; 14(5):e280-e294. PubMed ID: 29601250
[TBL] [Abstract][Full Text] [Related]
12. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW
J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778
[TBL] [Abstract][Full Text] [Related]
13. Examining the association between oncology drug clinical benefit and the time to public reimbursement.
Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW
Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
15. Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.
Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S34-S48. PubMed ID: 28535104
[TBL] [Abstract][Full Text] [Related]
16. The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China.
Bao Y; Liu Y; Ma R; Zhang P; Li X
J Glob Health; 2023 Nov; 13():04140. PubMed ID: 37934965
[TBL] [Abstract][Full Text] [Related]
17. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.
Michaeli DT; Mills M; Kanavos P
Appl Health Econ Health Policy; 2022 Sep; 20(5):757-768. PubMed ID: 35821360
[TBL] [Abstract][Full Text] [Related]
18. Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
Lemieux J; Audet S
Curr Oncol; 2018 Jun; 25(Suppl 1):S161-S170. PubMed ID: 29910659
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center.
Wilson L; Lin T; Wang L; Patel T; Tran D; Kim S; Dacey K; Yuen C; Kroon L; Brodowy B; Rodondi K
J Manag Care Spec Pharm; 2017 Feb; 23(2):163-169. PubMed ID: 28125363
[TBL] [Abstract][Full Text] [Related]
20. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
